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ORIGINAL ARTICLE
Preparation, characterization and in vitro evaluation of sterically
stabilized liposome containing a naphthalenediimide derivative as
anticancer agent
Amelia Parise1, Andrea Milelli1, Vincenzo Tumiatti1, Anna Minarini2, Paolo Neviani1, and Guendalina Zuccari1
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Abstract
The aim of this study was to incorporate a new naphthalenediimide derivative (AN169) with a
promising anticancer activity into pegylated liposomes to an extent that allows its in vitro and
in vivo testing without use of toxic solvent. AN169-loaded liposomes were prepared using the
thin-film hydration method and characterized for size, polydispersity index, drug content and
drug release. We examined their lyophilization ability in the presence of cryoprotectants
(trehalose, sucrose and lysine) and the long-term stability of the lyophilized products stored at
4 C for 3 and 6 months by particle size changes and drug leakage. AN169 was successfully
loaded into liposomes with an entrapment efficiency of 87.3 2.5%. The hydrodynamic
diameter of these liposomes after sonication was 145 nm with a high degree of
monodispersity. Trehalose was found to be superior to the other lyoprotectants. In particular,
trehalose 1:10 lipid:cryoprotectant molar ratio may provide stable lyophilized liposomes with
the conservation of physicochemical properties upon freeze-drying and long-term storage
conditions. We also assessed their in vitro antitumor activity in human cancer cell lines (HTLA-
230 neuroblastoma, Mel 3.0 melanoma, OVCAR-3 ovarian carcinoma and SV620 prostate cancer
cells). However, only after 72 h incubation, loaded liposomes showed almost the same IC50 as
free AN169. In conclusion, we developed a stable lyophilized liposomal formulation for
intravenous administration of AN169 as anticancer drug, with the advantage of avoiding the
use of potentially toxic solubilizing agents for future in vivo experiments.
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Introduction
Liposomes are extensively used as drug carriers since their first
description by Alec Bangham and colleagues in 1965. The
application of liposomes as drug delivery system has found
significantly clinical applications due to their versatility and
biocompatibility. Moreover, they display the ability to encap-
sulate drugs in their aqueous interior or to bind pharmaceut-
icals into or onto their lipid bilayer (Torchilin, 2005). However,
from the appearance of early papers, many efforts have been
done to overcome a number of problems associated with the
in vivo use of the conventional liposomes. A great disadvantage
of first formulation was the rapid clearance from circulation by
uptake into cells of the mononuclear phagocyte system. More
recently, significant increase in circulation time was obtained
by grafting of PEG to the liposome surface (Immordino et al.,
2006). The increase of surface hydrophilicity imparted by PEG
avoids opsonisation and allows vehicle distribution to other
tissue with a preferential accumulation in solid tumours
through the ‘‘enhanced permeability and retention’’ effect
(Milla et al., 2012). These long-circulating liposomes were
termed ‘‘Stealth’’ liposomes.
Today, there are many marketed liposomal formulations
for the treatment of cancer patients, for example, liposomal
doxorubicin Caelyx (Schering-Plough Corporation,
Kenilworth, NJ), Doxil (Janssen Biotech, Inc., Horsham,
PA) and vincristine Marqibo (Talon, San Francisco, CA), the
most recent liposomal formulation to receive FDA approval
(Allen, 2013). In vivo administration of such PEG-coated
phospholipid vesicles represents a useful and less toxic tool to
increase the therapeutic potential of anticancer drugs.
At the same time, the search for new compounds with
antitumor activity has become one of the main goals in
medicinal chemistry. One group of antiproliferative agents
used in cancer therapy comprises molecules that intercalate
DNA such as naphthalimides. Among these, the earliest drug
amonafide entered in clinical development, failed to reach
Phase III because of its toxicity. The therapeutic properties of
naphthalimides were subsequently improved by designing bis-
intercalating agents like naphthalenediimides (Ingrassia et al.,
2009).
Recently, we have synthesized a new series of naphthale-
nediimide derivatives endowed with two basic side chains
with the aim to enhance the interactions with the phosphate
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groups of DNA (Tumiatti et al., 2009). Moreover, we tried to
combine structural components of several antitumor com-
pounds into a single molecule valuating the influence of
different substituents on the aromatic rings towards different
cancer cell lines. Among the different molecules, submitted to
the Developmental Therapeutics Program at National Cancer
Institute for evaluation, one showed an interesting anticancer
activity against 60 human cancer cell lines. This compound,
named AN169 and characterized by a side chain length of
three methylene units and by two 2,3,4-trimethoxy benzyl
groups (Figure 1), was further investigated to elucidate the
molecular pathways involved in its growth inhibiting activity.
The drug was not patented to let its use to the all the scientific
community for better elucidate its mechanism of action
(Milelli et al., 2012).
However, one of the most serious limitations regarding the
pharmaceutical use of this new anticancer drug is was its low
solubility in physiological liquids. In particular, the in vitro
and in vivo assays needed dimethyl sulfoxide as solubilising
agent.
Therefore, in an attempt to avoid the use of organic solvent,
that does not allow a proper assessment of drug activity and
cytotoxicity, we propose here a liposomal system as a carrier
for AN169. More precisely, in this study, we report on the
preparation and characterization of AN169-loaded liposomes.
The objective of this study was to develop lyophilized
AN169-loaded liposomes that should have certain desirable
characteristics, such as intact cake without volume shrinkage,
short reconstitution time (instantaneous or upon gentle
manual shaking), desired size and polydispersity, acceptable
residual moisture level and preserved drug loading upon
lyophilization process and during storage. We also assessed
the effect of the optimized liposome formulation on the
growth of several human cancer cell lines in vitro. The
relevance of our novel liposomal nanomedicine could be in
providing a new tool for adjuvant therapy of cancer.
Methods
Materials
All the chemicals were purchased from Sigma Chemical Co.
(St. Louis, MO,). Hydrogenated soy phosphatidylcholine
(HSPC), cholesterol (CHOL), 1,2 distearoylglycero-3-phos-
phatidylethanolamine-N-polyethylene glycol-2000 (DSPE-
PEG) were from Avanti Polar Lipids, Inc. (Alabaster, AL).
[3H]cholesteryl hexadecyl ether (3[H]CHE) was obtained
from Perkin-Elmer Italia S.p.A. (Monza, Italy). AN169 was
synthesized as reported previously (Milelli et al., 2012).
Liposome preparation
Initially, multilamellar vesicles (MLVs) were prepared
according to the film hydration method using a standard
initial molar ratio of lipids (Pagnan et al., 1999;
Di Paolo et al., 2013). Briefly, HSPC:CHOL:DSPE-PEG,
2:1:0,1 molar ratio, were dissolved in chloroform at 10 mM.
In some preparations, 3[H]CHE was added as a non-
exchangeable, non-metabolizable lipid tracer to assess the
lipid content of liposomal dispersion using a scintillation
counter of beta luminescence (RadTech, Italy). Lipid was
quantified by liquid scintillation counting (LSC) of samples
containing a known quantity of 3[H]-CHE. AN169 was
dissolved in methanol and then combined with lipids at
various drug concentrations (0.25, 0.50, 1.0, 2.0 mg/mL). The
ratio of methanol and chloroform was 1:3. The lipid–drug
mixture was deposited as a thin film in a round-bottom flask
by roto-evaporating the organic solvents under vacuum. The
vacuum was applied for 1 h to ensure total removal of trace
solvent. The film was hydrated at a temperature above the
gel–liquid transition temperature of the amphiphiles (Tc) with
2 mL of phosphate-buffered saline (PBS) solution. The
resultant MLVs suspension was further sonicated (Sonopuls
HD 2070, Bandelin electronic GmbH & Co. KG, Berlin)
using a titanium probe (exponential micro-probe end diameter
3 mm) slightly immersed into the preparation. All the samples
were sonicated for 8 min at a power rating of 6 units at a
temperature above the Tc. This transformed the milky
suspension to a translucent suspension of small unilamellar
vesicles (SUVs). After sonication, the samples were left to
stand at 20–25 C (above the Tc) for 30 min prior to proceed
with subsequent experiments.
Determination of drug loading in liposomes
Each vesicle suspension was purified from non-incorporated
AN169 by gel chromatography on Sephadex G50 pre-
equilibrated with Hepes buffer (25 mm HEPES, 140 mm
NaCl, pH¼ 7.4). As gel chromatography isolation process is
based on molecular weight, liposomes pass more freely, due
to size restriction. On the contrary, free drug may enter the
pores in the bead, and the result is that a larger fraction of the
overall volume of the column is available to the drug, which
thus spends a longer time on the column and is eluted by the
mobile solvent after liposomes. After elution of the column
void volume, we obtained five opalescent fractions that
collected together had a volume of about 2.50 mL. To assess
the entrapment efficiency (EE%), expressed as a percentage
of the total amount of AN169 found in the studied formu-
lations at the end of the preparation procedure, liposomes
were at first disrupted, and then drug content was determined
by assaying for incorporated drug by Heios Thermo
spectronic UV–Visible spectrophotometer. Briefly, small
aliquots of liposomes (from 300 to 600 nmol of phospho-
lipids) were diluted to 2 mL with methanol, subjected to a
bath type sonication until liposomes disruption (10 min) and
analysed for drug content at ¼ 377 nm. For the preparation
of the calibrations curves, each concentration was analysed
five times (n¼ 5). The EE% was calculated from the amount
of incorporated drug divided by the total amount used at the
beginning of preparation multiplied by 100.
Dynamic light scattering (DLS) measurements
The Z-average particle size (hydrodynamic diameter), size















Figure 1. The chemical structure of AN169.
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dynamic light scattering (DLS) spectrophotometric measure-
ment with a 90Plus Nanoparticle Size Analyzer (Brookhaven
Instruments, Holtsville, NY) equipped with a 50 mW He-Ne
laser (532 nm) at 25 C. The scattering angle was fixed at
90. Results were the combination of three 10-minute runs
for a total accumulation correlation function (ACF) time
of 30 minutes. Prior to analysis, about 0.1 mL of fresh or
rehydrated liposomal suspension sample was diluted with
3 mL of Hepes buffer immediately after preparation. Changes
in mean diameter were also monitored during leakage
experiments carried out at 4 C for 14 days to assess the
stability of liposome formulations in storage conditions.
Withdrawals of small aliquots (20mL) of liposome suspen-
sions were diluted with Hepes buffer and analysed at days 1,
2, 3, 7, 10 and 14. Each measurement was repeated
three times.
Freeze drying of liposomes
Freshly prepared SUVs with or without the addition of
AN169 were mixed with different cryoprotectants: trehalose,
lysine, sucrose at 1:6, 1:8, 1:10, 1:12 lipid:cryoprotectant
(L:C) molar ratios. Briefly, 0.1 mL of liposome suspension
were mixed with aliquots amounts of the cryoprotectant stock
solutions to achieve a final lipid concentration of 2.5 mm and
quickly frozen with iced acetone, stored in a ultra low freezer
at –80 C overnight and lyophilized for 48 h using an ALPHA
1-4 LDplus freeze dryer (Christ Osterode, Germany) with a
condenser temperature of –55 C. The dried samples were
stored at 4 C for extended time period under nitrogen
atmosphere and reconstituted with sterile water to their
original concentrations prior to use (Kundu et al., 2012).
Suspensions were observed and evaluated for the rate of
reconstitution. For those samples, which failed to rehydrate
instantaneously upon addition of water by manual shaking,
reconstitution was attempted by vortexing for 1 min. The
resulting solutions were characterized and the results were
compared to the characteristics of the fresh formulations.
Moisture content analysis using thermogravimetric
technique
Thermogravimetric studies were carried out to measure the
moisture content of the loaded freeze-dried liposomes using a
TGA/SDTA 851e (Mettler Toledo Instruments) equipped with
STARe software. The thermogravimetric profiles were rec-
orded with a heating rate of 20 C/min from 25 to 140 C
under a nitrogen atmosphere (50 mL/min). The sample
weights ranged from 4 to 10 mg. The values reported are
the percentage loss in weight of the product.
Leakage and in vitro drug release stability of liposome
formulations
Leakage of AN169 from reconstituted samples were studied
at 4 C in HEPES buffer pH 7.4 directly after lyophilization
and after 3 and 6 months of storage at 4 C by dialysis
bag diffusion technique for 14 days, and compared to
freshly prepared formulations. One millilitre of the loaded
suspensions was placed in the dialysis bag (Spactra/Por Float-
A-Lyser G2, CE, m.w. cutoff: 100 kDa) hermetically sealed
and immersed into 20 mL of HEPES buffer pH 7.4. Samples
were withdrawn from the receptor compartment at predeter-
mined time intervals and replaced with fresh medium.
Aliquots were diluted with acetonitrile before being trans-
ferred to HPLC for the determination of drug content. The
HPLC assays were carried out by a Nova-Pak C18 (150 x
3.9 mm, 4 mm, Waters) column, UV detector at 377 nm. The
mobile phase was a mixture of water (20%) and acetonitrile
(80%); the injecting volume 20 mL; the flow rate 1.0 mL/min.
The system was thermostated at 37 C. In these conditions
retention time of AN169 was 9 min.
Release studies were carried out in HEPES buffer and 25%
FBS (Foetal Bovine Serum) at 37 C for 72 h on both freshly
prepared formulations and on reconstituted liposomes from
lyophilized powders at selected time points (directly after
freeze-drying, and after 3 and 6 months of storage at 4 C) by
a dialysis bag as above. The entire system was kept in thermal
bath with constant stirring. The cumulative release and the
drug leakage percentage were calculated by dividing the
cumulative amount of drug recovered in the dialysis medium
with the total amount in the liposomes. The samples were
protected from the ambient light during both leakage
experiments and drug release studies.
In vitro cytotoxicity assay
HTLA-230 neuroblastoma, Mel 3.0 melanoma, OVCAR-3
ovarian carcinoma and SV620 prostate cancer cells (donated
by Dr. L. Raffaghello, G. Gaslini Institute, Genoa, Italy) were
grown in Dulbecco’s modified Eagle medium (Euroclone,
Milan, Italy) supplemented with 10% foetal bovine serum
(GIBCO, Milan, Italy) and 50 UI/ml penicillin, 50 mg/ml
streptomycin and 2 mm L-glutamine (Euroclone, Milan,
Italy). Cells were cultured at 37 C in a humidified atmos-
phere of 5% CO2 in air.
The cytotoxicity of AN169-loaded liposome was compared
to that of free AN169. Briefly, drug stock solutions (1 10–
2 M) were prepared in cell culture DMSO. These were
initially diluted in phosphate buffer saline (1 10–3 M) and
finally in complete growth medium (1 10–4 M). Several mL
were taken and put into cell culture plates to obtain different
drug concentrations (highest final DMSO concentration was
0.05%). Liposomes were only diluted in growth medium. All
controls contained the highest DMSO concentration used in
the treated samples.
Cells were plated in 96-well tissue culture plates, allowed
to attach 24 hours, and then left untreated or treated with
growth medium containing 0.25, 0.50, 0.75, 1.0, 1.25, 1.5,
1.75, 2.0 mM of free or encapsulated AN169. Briefly, 15 mL of
5 mg/mL 3 -(4,5-diphenyltetrazolium) bromide (MTT) in PBS
were then added to each well and cells were incubated for 4 h
at 37 C. Formazan crystals were made soluble with DMSO.
Optical densities were determined at 570 nm using a
Dynatech MR5000 plate reader. Viability was expressed as
a percentage of control by dividing the absorbance of each
treated well by the average of the untreated controls.
Cytotoxicity was determined by plotting cell viability versus
drug concentrations. Results, derived from three different
experiments, are expressed as mean percentage from quad-
ruplicate wells as compared to that of control cells. The IC50
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of the tested compounds were estimated graphically from the
dose-response curves after 24 and 72 h of drug exposure.
Statistical analysis
Data were subjected to statistical analysis using the one-way
analysis of variance, and p values 50.05 were regarded as
significant. These experiments were expressed as a mean
values standard deviation (SD).
Results and discussions
Influence of AN 169 concentration on the entrapment
percentage and size
AN169 liposomes are intended to be administered by
intravenous route (IV). Therefore, their size and loading
represent two important parameters to guarantee the extrava-
sation of the therapeutic concentrations of AN169 within the
disease site. The thin layer evaporation method was chosen
due to its facility to enable the encapsulation of hydrophobic
drugs (Deniz et al., 2010). The hydrodynamic diameter of all
AN169 liposomes after sonication was 145 nm with a high
degree of monodispersity (Figure 2). The greater amount of
AN169 entrapped within liposomes was achieved using an
initial AN169 concentration of 2.0 mg/mL. However, the
amount of free AN169 to be recovered after the purification
step of the production process was high (0.98 mg/mL).
The reduction of the initial concentration of drug to 1.0 or
0.5 mg/mL led to a minor amount AN169 entrapped, but the
loss of unentrapped AN169 was lower indicating a better
efficiency in the production process. Finally, a further
reduction of the initial drug concentration to 0.25 mg/mL
led to a low loading of AN169. Thus, the drug concentration
used for the preparation of AN169-loaded SUVs was
1.0 mg/mL.
Effects of various cryoprotectants on lyophilized/
rehydrated liposomes
The potential application of liposome as therapeutic tool is
limited by their inherent chemical instabilities (e.g. lipid
oxidation and hydrolysis) and by physical factors such as
heating or freezing which accelerate drug release during
storage. To circumvent these problems and achieve long-term
stability of formulations, freeze-drying (lyophilization) has
been used as an effective approach to render liposomes stable
without compromising their size or encapsulation capacity
(Chengjun et al., 2010).
As first step, loaded and empty liposome formulations
were lyophilized without the use of cryoprotectants, as
polyethylene glycol has been shown to inhibit nucleation of
ice and thus ice crystal formation during freezing (Annunziata
et al., 2002). However, PEG-shell alone was not sufficient
to protect our stealth liposomes upon lyophilization, thus
both size and PI significantly increased (Z-average¼
3561 249 nm; PI¼ 0.86 0.17). Therefore, it was necessary
to add cryoprotectants to protect SUVs from fusion during
dehydration.
Three potential cryoprotectants were evaluated, sucrose,
trehalose and lysine, by determining their effect on liposome
size and PI after reconstitution. The freeze-drying efficiency
of sugars has been widely confirmed (Crowe et al., 1994),
while, more recently, it has been demonstrated that amino
acids represent an alternative class, for example, in diabetic
patients (Mohammed et al., 2007). As reflected in Table 1,






























Figure 2. Chemico-physical characterization of freshly prepared SUVs. (A) Influence of different initial AN169 concentrations on liposome size and
entrapment efficiency. Values are expressed as the mean S.D. (n¼ 3). aSignificant difference vs initial concentration of 2.00 mg/mL (p40.05). bNo
Significant difference versus initial concentration of 1.00 mg/mL (p50.05). cSignificant difference versus initial concentration of 0.50 mg/mL
(p50.05). dSignificant difference versus initial concentration of 0.25 mg/mL (p40.05). (B) Representative particle size distribution by intensity of
freshly prepared loaded liposomes.
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employed influenced cryoprotection efficacy. For example,
loaded liposomes, lyophilized in the presence of relatively
low 1:6, 1:8 L:C molar concentrations, were smaller com-
pared to unprotected ones, but their mean particle diameters
were still significantly increased (p50.05) compared to
liposome size prior to lyophilization; so neither sugars nor
lysine were capable of offering protection during freeze-
drying. Instead better results were achieved when the two
sugars were added at molar ratio of 1:10 L:C with trehalose
showing the more efficient stabilizing activity with non-
significant difference in size compared to freshly prepared
samples (p¼ 0.7 and p¼ 0.1 for trehalose and sucrose,
respectively). These findings indicate a successful lyophil-
ization cycle and cryoprotectant, whereas considerable par-
ticle growth and broad size distribution were observed with
lysine. The amino acid exerted only a slight protection, as
liposomes were always significantly larger as compared to
freshly prepared ones at each molar ratio tested (p values
between 0.01 and 0.03).
Of the evaluated cryoprotectants, for treahlose the results
were as expected, because this sugar displays a sufficiently
high glass transition temperature (T’g¼29 C) and is
small enough to interact with phospholipid head groups,
thus forming a glassy state during main drying (Hinrichs
et al., 2006). Also sucrose, even in a less extend, displays
an efficient protection during freeze-drying, while, on the
contrary, lysine showed no appreciable effect on the
investigated liposome. Lysine has a side chain with a
charged positive group, also the drug is characterised by the
presence of two amino groups protonated at pH 6–7. It may
be possible that the repulsion between the positively
charged molecules prevents the protection exerted by
lysine on the phospholipid membrane. In fact, comparison
of AN169-loaded vesicles with their empty freeze-dried
counterparts lyophilized in the presence of lysine revealed a
trend of increased vesicle size when AN169 was incorpo-
rated within the liposome bilayers. In contrast, the
lyophilized empty SUVs and the lyophilized loaded SUVs
showed similar behaviour for the two sugars, suggesting that
in this case AN169 does not interact with the cushioning
effect of cryoprotectants. One reasonable explanation could
be that one basic side chain of the AN169 molecule
protrudes from the outer margin of the bilayer. This
orientation is consistent with the high molecular ratio
between the drug and lipids in the final stage of formulation
(high drug-entrapment efficiency). Thus, the reason of the
different cryoprotection capability among the three com-
pounds may depend on the structural orientation of AN 169
within the lipid bilayer.
After selection of cryoprotectant, it is important to
optimize the concentration of the used cryoprotectant in
such a way that it should be used minimum while preserving
all desirable characteristics of the final product. In general, as
an increase in sugar to lipid ratio corresponds to a better
cryoprotective effect, in an additional experiment we
investigated if higher trehalose or sucrose concentrations
could improve the cryoprotective capability. As shown in
Figure 3, the optimal carbohydrate concentration for stabiliz-
ing such liposomes was found to be 1:10 L:C molar ratio.
However, further increase in the L:C resulted in a decrease in
cryprotection only for sucrose, while, in contrast, loaded
SUVs freeze-dried in the presence of trehalose, were still
spherical and uniform up to 1:20 L:C molar ratio; vesicles
fusion occurred only when molar concentration of 1:24 L:C
was employed. This biphasic nature of cryoprotectants has
previously been demonstrated (Suzuki et al., 1996), an initial
increase in concentration is often associated with a higher
uniformity of size while a further increase may often let to
aggregation and damage.
In summary, to achieve storage stability of liposomes by
freeze-drying procedure the addition of cryoprotectants is
absolutely necessary, irrespective of the surface-attached
polyethylenglycol, which is reported to be an effective cryo-
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Figure 3. (A) Changes in the mean diameter of reconstituted loaded
liposomes as a function of sucrose or trehalose concentrations. *Pre:
liposomal size prior to lyophilization. Data are the mean SD of three
independent experiments. (B) Representative particle size distribution by
intensity of lyophilized loaded SUVs cryoprotected with trehalose
1:10 L:C molar ratio.
Table 1. Effect of lipid to cryoprotectant (C:L) molar ratio on the vesicle size (nm) and polydispersity index (PI) of loaded SUVs.
Trehalose Sucrose Lysine
L:C Size PI Reconstitution Size PI Reconstitution Size PI Reconstitution
1:6 280 23 0.357 0.01 Manual shaking 393 34 0.254 0.02 Vortexing 452 49 0.420 0.02 Vortexing
1:8 190 15 0.221 0.05 Instantaneous 220 42 0.179 0.05 Manual shaking 484 18 0.382 0.07 Vortexing
1:10 147 10 0.183 0.03 Instantaneous 153 18 0.198 0.07 Instantaneous 639 57 0.574 0.03 Vortexing
Size and PI were determined by dynamic light scattering. Results shown are the mean SD from at least three independent batches of formulation upon
reconstitution.
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with trehalose and sucrose, while lysine seems to be less
suitable revealing high polydispersity indexes.
Residual moisture content in the lyophilized loaded
liposomes
The physicochemical properties of lyophilized products are
influenced by residual moisture content in the dried powders.
High values of moisture may also destabilize the delivery
systems during storage because of cryoprotectants crystal-
lization (amorphous collapse). Water may induce a shift in the
Tg (glass transition temperature) of the formulation to below
the temperature of storage, thus high residual water content
may initiate crystallization of the formulation during storage
and subsequent collapse of the product (Miller, 2006).
Acceptable residual moisture values range from 1% to 3%
w/w for most pharmaceutical products. Analysis of moisture
content of the loaded freeze-dried liposomes revealed that all
the formulations tested had low level of residual moisture
content immediately post-freeze-drying (Figure 4), in line
with the levels globally accepted by the regulatory authorities.
Thus, the presence of water concentration below 3% (w/w) in
freeze-dried products confers improved stability and drug
retention by preventing any chemical reactions that can occur
due to hydrolysis.
Drug retention efficiency of lyophilized SUVs
It is important that drug loading of the delivery system should
remain stable before and after the process of lyophilization.
Moreover, for commercialization of any pharmaceutical
formulation, it is a mandatory requirement to have long-
term stability of the final product. Hence, further study on the
stability not only in connection to the process of lyophiliza-
tion but also for long-term storage conditions is deemed
necessary.
Liposomes, if not efficaciously protected during freeze-
drying, can undergo membrane damage due to the formation
of ice crystals with extensive drug loss (Kirby, 1984).
Furthermore, instability of a liposome system in the drier
state, due for example to a gradual increase of residual
moisture content during storage, leads to aggregation or
fusion of liposomes, which in turn increases particle size and
drug leakage. Particles of greater diameter are taken rapidly
by the RES (reticuloendothelial system) resulting in their
rapid clearance and short half-life. For this purpose to
establish drug leakage under storage conditions we chose the
formulation cryoprotected with trehalose 1:10 L:C molar ratio
as it was characterized by the best physicochemical properties
(size, PI and residual moisture content). After reconstitution
in HEPES buffer, the lyophilized powders, stored at 4 C for 3
and 6 months, were maintained at 4 C for 14 days and their
release profiles were compared to those of freshly prepared
suspensions and to those of reconstituted samples immedi-
ately after freeze-drying. At the same time, we assessed
vesicle size as the retention of entrapped drug could modulate
the fluidity and rigidity of the phospholipid membrane.
As shown in Figure 5, drug leakage from fresh suspensions
was negligible up to 1 week (7.0 1.7%) with a slight
progressive increase. In the case of reconstituted formula-
tions, for any storage time all the samples showed a similar
loss of drug suggesting that freeze-drying did not affect
damage of the carrier system. In addition, the analysis of the
mean size revealed a little gradual aggregation over time
demonstrating that the constant maintenance of vesicle
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Figure 5. Analysis of leaking from the liposomal carrier at 4 C. After
freeze-drying loaded SUVs cryoprotected with trehalose 1:10 L:C molar
ratio were stored in the lyophilized state at 4 C and at selected time
points: immediately after freeze-drying, after 3 months and after 6
months were reconstituted with HEPES buffer. Rehydrated samples were
maintained at 4 C for 14 days and evaluated for vesicle mean diameter
(B) and drug loss (B). Release and size profiles were compared to freshly
prepared formulations to assess changes in stability after lyophilization
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Figure 4. Influence of cryoprotectants on moisture content after
freeze-drying. SUVs were freeze-dried with 10 mol of cryoprotectant
added per mol of the lipid. Moisture content was assessed by TGA. All
the values reported are the mean from three samples SD.
DOI: 10.3109/10717544.2013.861042 Sterically stabilized liposome 595
In vitro drug release of SUVs
For any controlled drug release formulation, effectiveness of
the preparation itself is primarily based on drug release
profile, which should remain in the desired profile for both
freshly prepared formulations and after storage. Therefore, in
this study, the in vitro drug release profiles of freshly prepared
liposomes were compared to those that were trehalose-
cryoprotected (1:10 L:C) and immediately reconstituted after
freeze-drying. At the same time, we studied if any changes in
the dried formulation occurred after 3 months and 6 months
long-term storage at 4 C. Figure 6 presents these drug release
profiles obtained at 37 C in PBS and 25% FBS by dialysis
method at different storage times. Notably, the differences in
the release profiles of lyophilized and non-lyophilized
liposomes were no statistically significant, and all types of
samples displayed sustained release of AN169, suggesting
that neither the process of freeze-drying, nor storage condi-
tions altered the drug release kinetics from PEG-liposomes.
Effect of liposomal AN169 on the growth of cancer
cells in vitro
The cytotoxic activity of liposomes encapsulated with AN169
was tested through the MTT assay on several cancer cell lines:
HTLA-230 neuroblastoma, Mel 3.0 melanoma, OVCAR-3
ovarian carcinoma and SV620 prostate cancer cells. Table 2
summarizes the IC50 values of the drug and drug loaded
liposomes at two different incubations times. However, the
AN169 formulation had higher IC50 values (decreased
cytotoxicity) compared to unincorporated AN169, while
only after 72 h incubation, loaded liposomes showed almost
the same IC50 as free AN169. These results may be related to
the steric hindrance from PEG chains on the liposome surface,
and also to the stability of liposome itself that retard the drug
release when the vesicles come into contact with medium and
cells (Crosasso et al., 2000).
Conclusions
Among desirable physicochemical characteristics of nanofor-
mulations, size, polydispersity and entrapment efficiency are
critical parameters that affect the in vivo performance of the
drug delivery systems. Our freshly prepared sterically
stabilized liposomes are characterized by a size of
147.3 6.5 nm with a polydispersity of 0.077 0.015 and
an entrapment efficiency of 87.3 2.5%. Instabilities of
liposome suspensions during storage are a serious limiting
factor for their applicability as drug delivery system. So, to
circumvent this problem, freeze-drying fresh formulations are
needed. Here, we have tested three different cryoprotectants,
trehalose, sucrose and lysine, but only sugars exerted an
efficacious protection during freeze-drying. In particular, the
results of this study demonstrated that trehalose 1:10 L:C
molar ratio may provide stable lyophilized liposomes with the
conservation of physicochemical properties upon lyophiliza-
tion and long-term storage conditions. This formulation has
the advantage of avoiding the use of potentially toxic solvents
for future in vivo experiments.
Based on these considerations, these results justify further
evaluation of AN169-loaded liposomes in cancer treatment.
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